SampleID | NumReplicates | Organism | TissueType | CellType | MHCAllele |
---|---|---|---|---|---|
SampleID | NumReplicates | Organism | TissueType | CellType | MHCAllele |
SYSMHC00073_TNBC_IFN_negative_rep1 | 6 | Human | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | ||
SYSMHC00073_TNBC_IFN_negative_rep2 | 6 | Human | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | ||
SYSMHC00073_TNBC_IFN_negative_rep3 | 6 | Human | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | ||
SYSMHC00073_TNBC_IFN_negative_rep4 | 9 | Human | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | ||
SYSMHC00073_TNBC_IFN_negative_rep5 | 9 | Human | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | ||
SYSMHC00073_TNBC_IFN_positive_rep4 | 9 | Human | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | ||
SYSMHC00073_MDA_MB231_Rep1_IFN_positive | 9 | Human | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | ||
SYSMHC00073_MDA_MB231_Rep1_IFN_positive_classII | 10 | Human | DRB1_0701,DRB1_1305,HLA-DPA10201-DPB11701,HLA-DQA10202-DQB10301 | ||
SYSMHC00073_MDA_MB231_Rep2_IFN_negative | 9 | Human | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | ||
SYSMHC00073_MDA_MB231_Rep3_IFN_positive_classII | 10 | Human | DRB1_0701,DRB1_1305,HLA-DPA10201-DPB11701,HLA-DQA10202-DQB10301 | ||
SYSMHC00073_MDAMB231_IFN_positive_rep5_Immuno_classI | 9 | Human | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | ||
SYSMHC00073_MDAMB231_IFN_positive_rep5_Immuno_classII | 10 | Human | DRB1_0701,DRB1_1305,HLA-DPA10201-DPB11701,HLA-DQA10202-DQB10301 |
ID | SampleID | RawFileName | Organism | Process | Tissue Type | Cell Type | Culture Conditions | Disease State | Comments | MHCClass | MHCAllele | PubMed ID | Peptide | Isolation Method | Antibody | Mass Spectrometer | LC System | iRT Peptides | Acquisition Mode | Fragmentation Method | Gradient | Gradient Length | Flow Rate | Replicate Number |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ID | SampleID | RawFileName | Organism | Process | Tissue_Type | Cell_Type | Culture_Conditions | Disease_State | Comments | MHCClass | MHCAllele | PubMed_ID | Peptide | Isolation_Method | Antibody | Mass_Spectrometer | LC_System | iRT_Peptides | Acquisition_Mode | Fragmentation_Method | Gradient | Gradient_Length | Flow_Rate | Replicate_Number |
SYSMHC00073 | SYSMHC00073_MDA_MB231_Rep1_IFN_positive | F120190510_PF_MDA_MB231_Rep1_IFN_positive_pool1.raw | Human | In vitro | Breast | MDA-MB-231 cell | adherent | Breast carcinoma | class I | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | PXD023038 | native | Immunoaffinity | W6/32 | Orbitrap Fusion Lumos | no | DDA | HCD | 0-80% ACN | 65 | 250 nl/min | 1 | ||
SYSMHC00073 | SYSMHC00073_MDA_MB231_Rep1_IFN_positive | F120190510_PF_MDA_MB231_Rep1_IFN_positive_pool2.raw | Human | In vitro | Breast | MDA-MB-231 cell | adherent | Breast carcinoma | class I | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | PXD023038 | native | Immunoaffinity | W6/32 | Orbitrap Fusion Lumos | no | DDA | HCD | 0-80% ACN | 65 | 250 nl/min | 2 | ||
SYSMHC00073 | SYSMHC00073_MDA_MB231_Rep1_IFN_positive | F120190510_PF_MDA_MB231_Rep1_IFN_positive_pool3.raw | Human | In vitro | Breast | MDA-MB-231 cell | adherent | Breast carcinoma | class I | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | PXD023038 | native | Immunoaffinity | W6/32 | Orbitrap Fusion Lumos | no | DDA | HCD | 0-80% ACN | 65 | 250 nl/min | 3 | ||
SYSMHC00073 | SYSMHC00073_MDA_MB231_Rep1_IFN_positive | F120190510_PF_MDA_MB231_Rep1_IFN_positive_pool4.raw | Human | In vitro | Breast | MDA-MB-231 cell | adherent | Breast carcinoma | class I | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | PXD023038 | native | Immunoaffinity | W6/32 | Orbitrap Fusion Lumos | no | DDA | HCD | 0-80% ACN | 65 | 250 nl/min | 4 | ||
SYSMHC00073 | SYSMHC00073_MDA_MB231_Rep1_IFN_positive | F120190510_PF_MDA_MB231_Rep1_IFN_positive_pool5.raw | Human | In vitro | Breast | MDA-MB-231 cell | adherent | Breast carcinoma | class I | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | PXD023038 | native | Immunoaffinity | W6/32 | Orbitrap Fusion Lumos | no | DDA | HCD | 0-80% ACN | 65 | 250 nl/min | 5 | ||
SYSMHC00073 | SYSMHC00073_MDA_MB231_Rep1_IFN_positive | F120190510_PF_MDA_MB231_Rep1_IFN_positive_pool6.raw | Human | In vitro | Breast | MDA-MB-231 cell | adherent | Breast carcinoma | class I | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | PXD023038 | native | Immunoaffinity | W6/32 | Orbitrap Fusion Lumos | no | DDA | HCD | 0-80% ACN | 65 | 250 nl/min | 6 | ||
SYSMHC00073 | SYSMHC00073_MDA_MB231_Rep1_IFN_positive | F120190510_PF_MDA_MB231_Rep1_IFN_positive_pool7.raw | Human | In vitro | Breast | MDA-MB-231 cell | adherent | Breast carcinoma | class I | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | PXD023038 | native | Immunoaffinity | W6/32 | Orbitrap Fusion Lumos | no | DDA | HCD | 0-80% ACN | 65 | 250 nl/min | 7 | ||
SYSMHC00073 | SYSMHC00073_MDA_MB231_Rep1_IFN_positive | F120190510_PF_MDA_MB231_Rep1_IFN_positive_pool8.raw | Human | In vitro | Breast | MDA-MB-231 cell | adherent | Breast carcinoma | class I | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | PXD023038 | native | Immunoaffinity | W6/32 | Orbitrap Fusion Lumos | no | DDA | HCD | 0-80% ACN | 65 | 250 nl/min | 8 | ||
SYSMHC00073 | SYSMHC00073_MDA_MB231_Rep1_IFN_positive | F120190510_PF_MDA_MB231_Rep1_IFN_positive_pool9.raw | Human | In vitro | Breast | MDA-MB-231 cell | adherent | Breast carcinoma | class I | HLA-A02:01,HLA-A01:17,HLA-B40:02,HLA-B41:01,HLA-C02:02,HLA-C17:01 | PXD023038 | native | Immunoaffinity | W6/32 | Orbitrap Fusion Lumos | no | DDA | HCD | 0-80% ACN | 65 | 250 nl/min | 9 |